Iovance Lucks Out With Amtagvi

The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.

After a long and pitfall-strewn campaign, Iovance Biotherapeutics, Inc. has finally scored US accelerated approval of its T-cell therapy lifileucel for certain melanoma patients. The company’s share price rose by 33% to $12.14 after the close on 16 February on the NASDAQ, presumably on investors’ sheer relief.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.